- Previous Close
1.5100 - Open
1.5500 - Bid 1.5300 x 100
- Ask 1.5800 x 700
- Day's Range
1.4900 - 1.5500 - 52 Week Range
0.9200 - 3.7300 - Volume
2,795,961 - Avg. Volume
2,867,150 - Market Cap (intraday)
556.698M - Beta (5Y Monthly) 1.29
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7800 - Earnings Date Nov 6, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.20
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
www.lexpharma.comRecent News: LXRX
View More
Performance Overview: LXRX
Trailing total returns as of 9/26/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LXRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LXRX
View MoreValuation Measures
Market Cap
556.70M
Enterprise Value
347.52M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
110.70
Price/Book (mrq)
2.32
Enterprise Value/Revenue
95.45
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-35.69%
Return on Equity (ttm)
-94.81%
Revenue (ttm)
3.64M
Net Income Avi to Common (ttm)
-202.11M
Diluted EPS (ttm)
-0.7800
Balance Sheet and Cash Flow
Total Cash (mrq)
309.96M
Total Debt/Equity (mrq)
44.03%
Levered Free Cash Flow (ttm)
-116.79M
Research Analysis: LXRX
View MoreCompany Insights: LXRX
LXRX does not have Company Insights
Research Reports: LXRX
View MoreDaily – Vickers Top Buyers & Sellers for 10/13/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Insider Picks for 09/20/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 09/19/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 09/18/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.